Generics in China
SUMMARY
Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
SYNOPSIS
Essential resource for top-line data and analysis covering the China generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
KEY HIGHLIGHTS
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The market value is evaluated at ex-factory prices.
Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
Please note that any volumes of '1' (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
All currency conversions were calculated at constant average annual 2016 exchange rates.
The Chinese generics market had total revenues of $57,010.8m in 2016, representing a compound annual growth rate (CAGR) of 14.4% between 2012 and 2016.
Market consumption volumes declined with a compound annual rate of change (CARC) of -1% between 2012 and 2016, to reach a total of 84.6% of total pharmaceutical volume in 2016.
Growth will continue at a lesser rate than in previous years as the government puts emphasis on Chinese businesses and increases patent powers.
SCOPE
NOTE: Out of security concerns MarketLine requires using corporate email address.
SUMMARY
Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
SYNOPSIS
Essential resource for top-line data and analysis covering the China generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
KEY HIGHLIGHTS
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The market value is evaluated at ex-factory prices.
Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
Please note that any volumes of '1' (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
All currency conversions were calculated at constant average annual 2016 exchange rates.
The Chinese generics market had total revenues of $57,010.8m in 2016, representing a compound annual growth rate (CAGR) of 14.4% between 2012 and 2016.
Market consumption volumes declined with a compound annual rate of change (CARC) of -1% between 2012 and 2016, to reach a total of 84.6% of total pharmaceutical volume in 2016.
Growth will continue at a lesser rate than in previous years as the government puts emphasis on Chinese businesses and increases patent powers.
SCOPE
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in China
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in China
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the China generics market with five year forecasts by both value and volume
- What was the size of the China generics market by value in 2016?
- What will be the size of the China generics market in 2021?
- What factors are affecting the strength of competition in the China generics market?
- How has the market performed over the last five years?
- How large is China’s generics market in relation to its regional counterparts?
NOTE: Out of security concerns MarketLine requires using corporate email address.
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan N.V.
Novartis AG
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan N.V.
Novartis AG
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
LIST OF TABLES
Table 1: China generics market value: $ billion, 2012-16
Table 2: China generics market volume: % of total pharma volume, 2012-16
Table 3: China generics market geography segmentation: $ billion, 2016
Table 4: China generics market value forecast: $ billion, 2016-21
Table 5: China generics market volume forecast: % of total pharma volume, 2016-21
Table 6: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 7: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 8: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 9: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 10: Mylan N.V.: key facts
Table 11: Mylan N.V.: key financials ($)
Table 12: Mylan N.V.: key financial ratios
Table 13: Novartis AG: key facts
Table 14: Novartis AG: key financials ($)
Table 15: Novartis AG: key financial ratios
Table 16: Teva Pharmaceutical Industries Limited: key facts
Table 17: Teva Pharmaceutical Industries Limited: key financials ($)
Table 18: Teva Pharmaceutical Industries Limited: key financial ratios
Table 19: China size of population (million), 2012-16
Table 20: China gdp (constant 2005 prices, $ billion), 2012-16
Table 21: China gdp (current prices, $ billion), 2012-16
Table 22: China inflation, 2012-16
Table 23: China consumer price index (absolute), 2012-16
Table 24: China exchange rate, 2012-16
Table 1: China generics market value: $ billion, 2012-16
Table 2: China generics market volume: % of total pharma volume, 2012-16
Table 3: China generics market geography segmentation: $ billion, 2016
Table 4: China generics market value forecast: $ billion, 2016-21
Table 5: China generics market volume forecast: % of total pharma volume, 2016-21
Table 6: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 7: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 8: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 9: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 10: Mylan N.V.: key facts
Table 11: Mylan N.V.: key financials ($)
Table 12: Mylan N.V.: key financial ratios
Table 13: Novartis AG: key facts
Table 14: Novartis AG: key financials ($)
Table 15: Novartis AG: key financial ratios
Table 16: Teva Pharmaceutical Industries Limited: key facts
Table 17: Teva Pharmaceutical Industries Limited: key financials ($)
Table 18: Teva Pharmaceutical Industries Limited: key financial ratios
Table 19: China size of population (million), 2012-16
Table 20: China gdp (constant 2005 prices, $ billion), 2012-16
Table 21: China gdp (current prices, $ billion), 2012-16
Table 22: China inflation, 2012-16
Table 23: China consumer price index (absolute), 2012-16
Table 24: China exchange rate, 2012-16
LIST OF FIGURES
Figure 1: China generics market value: $ billion, 2012-16
Figure 2: China generics market volume: % of total pharma volume, 2012-16
Figure 3: China generics market geography segmentation: % share, by value, 2016
Figure 4: China generics market value forecast: $ billion, 2016-21
Figure 5: China generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in China, 2016
Figure 7: Drivers of buyer power in the generics market in China, 2016
Figure 8: Drivers of supplier power in the generics market in China, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 11: Drivers of degree of rivalry in the generics market in China, 2016
Figure 12: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 13: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
Figure 14: Mylan N.V.: revenues & profitability
Figure 15: Mylan N.V.: assets & liabilities
Figure 16: Novartis AG: revenues & profitability
Figure 17: Novartis AG: assets & liabilities
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities
COMPANIES MENTIONED
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan N.V.
Novartis AG
Teva Pharmaceutical Industries Limited
Skip to top
Figure 1: China generics market value: $ billion, 2012-16
Figure 2: China generics market volume: % of total pharma volume, 2012-16
Figure 3: China generics market geography segmentation: % share, by value, 2016
Figure 4: China generics market value forecast: $ billion, 2016-21
Figure 5: China generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in China, 2016
Figure 7: Drivers of buyer power in the generics market in China, 2016
Figure 8: Drivers of supplier power in the generics market in China, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 11: Drivers of degree of rivalry in the generics market in China, 2016
Figure 12: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 13: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
Figure 14: Mylan N.V.: revenues & profitability
Figure 15: Mylan N.V.: assets & liabilities
Figure 16: Novartis AG: revenues & profitability
Figure 17: Novartis AG: assets & liabilities
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities
COMPANIES MENTIONED
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan N.V.
Novartis AG
Teva Pharmaceutical Industries Limited
Nano-Enabled Packaging for the Pharmaceutical Industry: a Technology, Industry and Market Analysis
US$ 3,250.00
Mar, 2010 · 93 pages
